Schizophrenia and Schizophrenia Spectrum PsychosisNCT07234708
Feeling Safe Study
A study testing Sentirnos Seguros in people with Schizophrenia and Schizophrenia Spectrum Psychosis, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
Trial summary
The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Schizophrenia and Schizophrenia Spectrum Psychosis
- What is being tested?
- Sentirnos Seguros
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 35 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jul 2025to 1 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men and women aged 18 years and older
- Diagnosis of schizophrenia spectrum disorders and other psychotic disorders according to DSM-5
- Score ≥ 4 on the delusions item of the Positive and Negative Syndrome Scale (PANSS)
- Presence of ideas of persecution with a degree of conviction > 60% in the last 3 months
Who cannot join
- Presence of intellectual disability
- Meet DSM-5 criteria for other mental health disorders, except for substance-related and addictive disorders
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Spain1 site, 1 recruiting
- Recruiting
Department of Psychiatry. Hospital Santa Creu i Sant Pau
Barcelona, 08025
Eva Grasa, PhD Psychologist, +34 93 553 78 40, egrasa@santpau.cat
About this study
Official title: Feeling Safe: Feasibility and Acceptability Study Evaluating a New Psychological Intervention for People With Psychosis and Positive Delusional Symptoms
The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.
The main questions it aims to answer are:
- Study participants will report high levels of acceptability and satisfaction with the Sentirnos Seguros programme.
- The Sentirnos Seguros intervention will be beneficial for participants at a clinical and functional level, with higher scores in the post-treatment phase compared to the pre-treatment phase.
Read the detailed description
This is a prospective, non-randomised feasibility pilot study with a before-and-after design.
The aims of the study are:
- Assess the feasibility, acceptability, and satisfaction after receiving the Sentirnos Seguros programme in people with schizophrenia spectrum disorder and positive delusional symptoms.
- Evaluate the clinical and functional benefits and safety of the Sentirnos Seguros programme.
- Being tested
- Sentirnos Seguros
- Keywords
- Feeling Safe, Schizophrenia, Acceptability, Feasibility
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sentirnos SegurosOther
The Sentirnos Seguros (Feeling Safe) programme is modular, personalised and includes the patient's preferences. The following modules are offered: improving sleep, reducing worry, increasing self-confidence, reducing the impact of voices, and feeling safe enough.
| Study group | Role | What they receive |
|---|---|---|
| Intervention | Experimental | Not described Receives: Other: Sentirnos Seguros |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance related to the total number of successful appointments made
Compliance will be assessed by calculating the frequency of successful appointments from baseline to 6 months (end of therapy)
Measured: From baseline to 6 months (end of therapy)
Number of drop-outs
The number of drop-outs will be assessed by calculating the proportion of participants who do not complete the study protocol
Measured: From baseline to 6 months (end of treatment)
Acceptability, measured with an ad hoc questionnaire
Acceptability with the intervention will be assessed by an ad hoc questionnaire to measure the dimensions of acceptability: perceived utility, perceived ease of use, barriers, and intention to use
Measured: From baseline to 6 months (end of the treatment)
Satisfaction with the intervention, measured with the Client Satisfaction Questionnaire (CSQ-8)
Satisfaction with the intervention will be assessed using the CSQ-8. A 4-point Likert scale is used to rate each item (1 = very dissatisfied; 4 = very satisfied), yielding a total score ranging from 8 to 32. A low score (close to 8) indicates low satisfaction with the services received, and a high score (close to 32) indicates high satisfaction with them.
Measured: From baseline to 6 months (end of the treatment)
Secondary outcomes (14)
Change in the severity of psychotic symptoms, measured with the Positive and Negative Syndrome Scale (PANSS)
The severity of psychotic symptoms will be assessed using the PANSS. This scale includes 30 items (7 for positive symptoms, 7 for negative symptoms, and 16 for general psychopathology). A 7-point Likert scale is used to rate each item (1 = not present; 7= most severe). The total score is the sum of all items. No specific cut-off scores have been established for the PANSS. The higher the score, the greater the clinical severity.
Measured: Changes in baseline scores at 6 months
Change in severity of hallucinations and delusions, measured with the Psychotic Symptom Rating Scales (PSYRATS)
The severity of hallucinations and delusions will be assessed using the PSYRATS. It consists of two subscales, one for hallucinations and one for delusions, each with 17 items, with Likert-type responses ranging from 0 to 5. The final score is obtained by adding the scores for each item. It can range from 0 to 44. No specific cut-off scores have been established for the PSYRATS. The higher the score, the more severe the hallucinations/delusions.
Measured: Changes in baseline scores at 6 months
Change in depression severity, measured with the Calgary Depresión Scale for Schizophrenia (CDSS)
The depression severity is assessed using the CDSS. This scale includes 9 items that are scored with a Likert scale that ranges from 0 (absent) to 3 (severe). The total score is the sum of all items. The higher the score, the greater the clinical severity. To identify the absence/presence of depression, a score ≥ 5 is the cut-off point.
Measured: Changes in baseline scores at 6 months
Change in the delusional conviction severity measured with the delusional conviction-analogue visual scale (DC-VAS)
Change in the delusional conviction severity will be assessed using the DC-VAS. This scale rates the degree of conviction of the delusional idea from 0 to 10.
Measured: Changes in baseline scores at 6 months
Change in core beliefs, measured with the Brief Core Schema Scales (BSCC)
The change in core beliefs will be assessed using the BCSS. This scale assesses an individual's core beliefs about themselves and others using a 5-point Likert scale (0-4). It comprises 24 items, yielding four scores: negative-self, positive-self, negative-others, and positive-others. Each score is based on six items. No specific cut-off scores have been established for the BCSS, scores are generally interpreted within a range. Higher scores generally indicate a greater endorsement of the beliefs represented by that subscale.
Measured: Changes in baseline scores at 6 months
Change in safety behaviour severity, measured with the Safety Behaviour Questionnaire (SBQ)
The safety behaviour severity will be assessed using the SBQ. This scale consists of 56 items rated on a 4-point Likert scale, where 0 = never and 3 = always. Specific cut-off scores haven't been established for the SBQ. Higher scores indicate greater frequency of use of safety behaviours.
Measured: Changes in baseline score at 6 months
Change in paranoid ideation, measured with the Spanish Green Paranoid Thought Scale (S-GPTS)
The change in paranoid ideation will be assessed using the S-GPTS. This scale consists of a total of 32 items rated on a 5-point Likert scale from 1 (Not at all) to 5 (Completely). The items are grouped into two scales of 16 items. Scale A assesses social reference ideas relevant to paranoia, while Scale B assesses persecutory thoughts. Scores on each scale range from 16 to 80 points, with higher scores reflecting a greater level of paranoid thinking. No cut-off points have been established.
Measured: Changes in baseline scores at 6 months
Change in functioning severity, measured with the Personal and Social Performance scale (PSP)
The change in functioning severity will be assessed using the PSP scale. The PSP scale evaluates four domains: Socially Useful Activities, Personal and Social Relationships, Self-Care, and Disturbing and Aggressive Behaviours. Each domain is rated on a 6-point severity scale, which is then converted into a 10-point band score for that domain. A total score is derived from the four domain scores, resulting in a single score between 1 and 100. No cut-off score is available. Higher scores indicate better functioning across all domains, with more severe functional difficulties reflected in lower scores.
Measured: Changes in baseline scores at 6 months
Change in self-perceived functionality severity, measured with the Self-perceived Functionality in people with Psychotic disorders (FAP-10)
The change in self-functionality will be assessed using the FAP-10. This questionnaire includes 10 items that are scored on a Likert scale ranging from 4 (Always) to 0 (Never). The total score is the sum of the scores for each item. The total score ranges from 0 (poor functionality) to 40 (excellent functionality).
Measured: Changes in baseline scores at 6 months
Change in quality of life, measured with the Quality of Life Index (QLI-sp)
The change in quality of life will be assessed using the QLI-sp. It is a 10-item questionnaire that assesses various aspects of health-related quality of life. It is scored on a scale of 1 to 10 points, with a higher score corresponding to a better quality of life. No cut-off scores are available.
Measured: Changes in baseline scores at 6 months
Change in recovery, measured with the Questionnaire about the Process of Recovery (QPR)
The change in recovery will be assessed using the QPR. It is a 15-item scale. Each item is rated on a 5-point Likert scale, from 0 (strongly disagree) to 4 (strongly agree), and the items are added together to obtain a total recovery score. Higher scores indicate greater recovery. No cut-off scores are available.
Measured: Change in baseline scores at 6 months
Change in clinic insight, measured with the Scale Unawareness of Mental Disorders (SUMD)
The change in clinic insight will be assessed using the SUMD. It consists of three items that explore the degree of insight a person has into their mental disorder, the effects of medication, and the social consequences. Each item is scored from 0 to 5, where 0 indicates that the item is not relevant or cannot be assessed, and 5 indicates a lack of awareness. No cut-off points are available.
Measured: Changes in baseline scores at 6 months
Change in cognitive insight, measured with the Beck Cognitive Insight Scale (BCIS)
The change in cognitive insight will be assessed using the BCIS. The BCIS assesses cognitive insight, specifically self-reflectiveness and self-certainty, in individuals with psychosis. It's a 15-item self-report measure where participants rate their agreement with statements on a scale of 0 to 3. The BCIS yields two subscale scores (self-reflectiveness and self-certainty) and a composite Reflectiveness-Certainty (R-C) index score. The R-C index is calculated by subtracting the self-certainty score from the self-reflectiveness score. Higher R-C index scores indicate greater cognitive insight. Cut-off scores: low cognitive insight, scores of 3 and below; moderate cognitive insight, scores of 4 to 9; and high cognitive insight, scores of 10 and above.
Measured: Changes in baseline scores at 6 months
Presence of adverse events, measured with an ad hoc clinical interview
Safety during the intervention will be assessed by collecting the presence of adverse events using an ad hoc clinical interview
Measured: From baseline to 6 months (end of the intervention)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2025
- Study start1 Jul 2025
- Primary completion1 Mar 2028 (estimated)
- Study completion1 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Schizophrenia and Schizophrenia Spectrum PsychosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07234708
- Sponsor's protocol ID
- IIBSP-SEG-2024-186
- Status last verified
- Nov 2025
- First submitted
- 28 Jul 2025
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feeling Safe: Feasibility and Acceptability Study Evaluating a New Psychological Intervention for People With Psychosis and Positive Delusional Symptoms
- ClinicalTrials.gov ID
- NCT07234708
- Acronym / sponsor ID
- IIBSP-SEG-2024-186
- Keywords
- Feeling Safe, Schizophrenia, Acceptability, Feasibility
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauUniversity, hospital or other
- Study start
- 1 Jul 2025 (actual)
- Primary completion
- 1 Mar 2028 (estimated)
- Study completion
- 1 May 2028 (estimated)
- First posted
- 18 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to assess the acceptability and satisfaction with the psychological intervention Sentirnos Seguros (Feeling Safe) in people with psychotic disorders and positive delusional symptoms.
The main questions it aims to answer are:
- Study participants will report high levels of acceptability and satisfaction with the Sentirnos Seguros programme.
- The Sentirnos Seguros intervention will be beneficial for participants at a clinical and functional level, with higher scores in the post-treatment phase compared to the pre-treatment phase.
Detailed description
This is a prospective, non-randomised feasibility pilot study with a before-and-after design.
The aims of the study are:
- Assess the feasibility, acceptability, and satisfaction after receiving the Sentirnos Seguros programme in people with schizophrenia spectrum disorder and positive delusional symptoms.
- Evaluate the clinical and functional benefits and safety of the Sentirnos Seguros programme.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention | Experimental | Other: Sentirnos Seguros |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Men and women aged 18 years and older
- Diagnosis of schizophrenia spectrum disorders and other psychotic disorders according to DSM-5
- Score ≥ 4 on the delusions item of the Positive and Negative Syndrome Scale (PANSS)
- Presence of ideas of persecution with a degree of conviction > 60% in the last 3 months
Key exclusion criteria (2 listed)
- Presence of intellectual disability
- Meet DSM-5 criteria for other mental health disorders, except for substance-related and addictive disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sentirnos SegurosThe Sentirnos Seguros (Feeling Safe) programme is modular, personalised and includes the patient's preferences. The following modules are offered: improving sleep, reducing worry, increasing self-confidence, reducing the impact of voices, and feeling safe enough. | Other | Intervention |
Primary outcome
Compliance related to the total number of successful appointments made
Time frame: From baseline to 6 months (end of therapy)
Compliance will be assessed by calculating the frequency of successful appointments from baseline to 6 months (end of therapy)
Number of drop-outs
Time frame: From baseline to 6 months (end of treatment)
The number of drop-outs will be assessed by calculating the proportion of participants who do not complete the study protocol
Acceptability, measured with an ad hoc questionnaire
Time frame: From baseline to 6 months (end of the treatment)
Acceptability with the intervention will be assessed by an ad hoc questionnaire to measure the dimensions of acceptability: perceived utility, perceived ease of use, barriers, and intention to use
Satisfaction with the intervention, measured with the Client Satisfaction Questionnaire (CSQ-8)
Time frame: From baseline to 6 months (end of the treatment)
Satisfaction with the intervention will be assessed using the CSQ-8. A 4-point Likert scale is used to rate each item (1 = very dissatisfied; 4 = very satisfied), yielding a total score ranging from 8 to 32. A low score (close to 8) indicates low satisfaction with the services received, and a high score (close to 32) indicates high satisfaction with them.
14 secondary outcomes
Change in the severity of psychotic symptoms, measured with the Positive and Negative Syndrome Scale (PANSS)
Time frame: Changes in baseline scores at 6 months
Change in severity of hallucinations and delusions, measured with the Psychotic Symptom Rating Scales (PSYRATS)
Time frame: Changes in baseline scores at 6 months
Change in depression severity, measured with the Calgary Depresión Scale for Schizophrenia (CDSS)
Time frame: Changes in baseline scores at 6 months
Change in the delusional conviction severity measured with the delusional conviction-analogue visual scale (DC-VAS)
Time frame: Changes in baseline scores at 6 months
Change in core beliefs, measured with the Brief Core Schema Scales (BSCC)
Time frame: Changes in baseline scores at 6 months
Change in safety behaviour severity, measured with the Safety Behaviour Questionnaire (SBQ)
Time frame: Changes in baseline score at 6 months
Change in paranoid ideation, measured with the Spanish Green Paranoid Thought Scale (S-GPTS)
Time frame: Changes in baseline scores at 6 months
Change in functioning severity, measured with the Personal and Social Performance scale (PSP)
Time frame: Changes in baseline scores at 6 months
Change in self-perceived functionality severity, measured with the Self-perceived Functionality in people with Psychotic disorders (FAP-10)
Time frame: Changes in baseline scores at 6 months
Change in quality of life, measured with the Quality of Life Index (QLI-sp)
Time frame: Changes in baseline scores at 6 months
Change in recovery, measured with the Questionnaire about the Process of Recovery (QPR)
Time frame: Change in baseline scores at 6 months
Change in clinic insight, measured with the Scale Unawareness of Mental Disorders (SUMD)
Time frame: Changes in baseline scores at 6 months
Change in cognitive insight, measured with the Beck Cognitive Insight Scale (BCIS)
Time frame: Changes in baseline scores at 6 months
Presence of adverse events, measured with an ad hoc clinical interview
Time frame: From baseline to 6 months (end of the intervention)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Schizophrenia and Schizophrenia Spectrum Psychosis
Recruiting
Supporting Patients by Family Education in Psychotic Illness: A Prospective Cohort Study
Psychotic Disorders, Family Members
RecruitingObservational study
The ATP Project (Antipsychotic-TEP-Psychosis)
First Episose Psychosis, Metabolic Disease
RecruitingPhase 2
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia
Schizophrenia
RecruitingPhase 2
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Schizophrenia
Not yet recruiting
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sentirnos Seguros in people with Schizophrenia and Schizophrenia Spectrum Psychosis, run by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Eva Grasa, PhD Psychologist (+34 93 553 78 40, egrasa@santpau.cat), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance related to the total number of successful appointments made (time frame: From baseline to 6 months (end of therapy)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.